Gregory Mullen
Geschäftsführer bei Ariceum Therapeutics GmbH
Profil
Gregory Edgar Mullen currently works at Theragnostics Ltd., as Director from 2017 and Ariceum Therapeutics GmbH, as Chief Operating Officer.
Aktive Positionen von Gregory Mullen
Unternehmen | Position | Beginn |
---|---|---|
Theragnostics Ltd.
Theragnostics Ltd. Medical SpecialtiesHealth Technology Part of Ariceum Therapeutics GmbH, Theragnostics Ltd. is a British company that develops and distributes diagnostic devices and therapeutics. The company is based in London, UK. The company was founded in 2013. Theragnostics was acquired by Ariceum Therapeutics GmbH on June 01, 2023 for $54.53 million. | Direktor/Vorstandsmitglied | 16.01.2017 |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Geschäftsführer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Theragnostics Ltd.
Theragnostics Ltd. Medical SpecialtiesHealth Technology Part of Ariceum Therapeutics GmbH, Theragnostics Ltd. is a British company that develops and distributes diagnostic devices and therapeutics. The company is based in London, UK. The company was founded in 2013. Theragnostics was acquired by Ariceum Therapeutics GmbH on June 01, 2023 for $54.53 million. | Health Technology |
Ariceum Therapeutics GmbH
Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021. | Commercial Services |